South Korea-based Samsung Biologics (207940.KS) has signed a strategic partnership with Kanaph Therapeutics, it was reported on Wednesday.
The contract has been signed to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
According to Kanaph Therapeutics, the product is aimed at autoimmune diseases by inhibiting the alternative pathway of the complement system. According to the contract, Samsung Biologics is to offer a complete scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission.
Nanjing Leads Biolabs receives FDA approval of IND application for LBL-047
J & D Pharmaceuticals receives Orphan Drug Designation for JD-004
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor
ImmuPharma files patent for P140 'Immunormalizer' with precision diagnostic for autoimmune diseases
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Bio-Thera and STADA expand biosimilars partnership to include tocilizumab
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
Novartis reports positive Phase III trial results for ianalumab in immune thrombocytopenia
Novartis reports positive Phase III results for ianalumab in Sjögren's disease
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
Formation Bio licenses IMIDomics' anti-CD226 autoimmune programme